Cargando…

Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea

INTRODUCTION: The quadrivalent inactivated split-virion influenza vaccine (QIV; VaxigripTetra(®)) was initially licensed in South Korea in 2017 for immunization against seasonal influenza in those aged ≥ 3 years, with the indicated age subsequently lowered to include those aged ≥ 6 months in 2018. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choe, Sunho, Talanova, Oxana, Shin, Sooyoun, Syrkina, Olga, Fournier, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257373/ https://www.ncbi.nlm.nih.gov/pubmed/37300743 http://dx.doi.org/10.1007/s40121-023-00825-x

Ejemplares similares

Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea
por: Lim, Sookyung, et al.
Publicado: (2022)

Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults
por: Montomoli, Emanuele, et al.
Publicado: (2018)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
por: Latreille-Barbier, Mathilde, et al.
Publicado: (2017)

Assessment of the influenza vaccine (VAXIGRIP) in triggering a humoural immune response
por: Mahallawi, Waleed H.
Publicado: (2017)

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
por: Syrkina, Olga, et al.
Publicado: (2022)

Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16
por: Bricout, Hélène, et al.
Publicado: (2017)

Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months–55 years
por: Yoo, Byung Wook, et al.
Publicado: (2019)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

La vaccinazione universale dei bambini contro l’influenza con il vaccino Vaxigrip Tetra(®) in Italia: risultati di una valutazione di Health Technology Assessment (HTA)
por: Boccalini, Sara, et al.
Publicado: (2018)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older
por: Thiem, Vu Dinh, et al.
Publicado: (2020)

Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study
por: Stefanizzi, Pasquale, et al.
Publicado: (2021)

Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months
por: Lee, Jee Hyun, et al.
Publicado: (2019)

Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
por: Wei, Xia, et al.
Publicado: (2023)

Improved post-marketing safety surveillance of quadrivalent inactivated influenza vaccine in Mexico using a computerized, SMS-based follow-up system
por: Betancourt-Cravioto, Miguel, et al.
Publicado: (2021)

Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season
por: Chabanon, Anne Laure, et al.
Publicado: (2017)

1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents
por: Díez-Domingo, Javier, et al.
Publicado: (2023)

Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015
por: Choe, Young June, et al.
Publicado: (2022)

Aqua(μ-cone-26,28-dibutoxy-25,27-bis{N-[5-(dimethylamino)naphthalene-1-sulfonyl]carbamoylmethoxy}-5,11,17,23-tetrakis(1,1-dimethylethyl)calix[4]arene(2−))disodium acetonitrile tetrasolvate
por: Dinake, Pogisego, et al.
Publicado: (2012)

Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis
por: de Lusignan, Simon, et al.
Publicado: (2018)

Influenza surveillance in Western Turkey in the era of quadrivalent vaccines: A 2003–2016 retrospective analysis
por: Meşe, Sevim, et al.
Publicado: (2018)

National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21
por: Tsai, Szu-Ying, et al.
Publicado: (2022)

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine
por: Domnich, Alexander, et al.
Publicado: (2023)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea
por: Han, Su-Eun, et al.
Publicado: (2018)

Diet of children under the government-funded meal support program in Korea
por: Kwon, Sooyoun, et al.
Publicado: (2010)

The Risk of Colorectal Cancer After Cholecystectomy or Appendectomy: A Population-based Cohort Study in Korea
por: Lee, Joonki, et al.
Publicado: (2018)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Validity of Self-reported Stroke and Myocardial Infarction in Korea: The Health Examinees (HEXA) Study
por: Choe, Sunho, et al.
Publicado: (2019)

Effects of students' satisfaction with school meal programs on school happiness in South Korea
por: Kwon, Sooyoun, et al.
Publicado: (2018)

National post-market surveillance assessment of veterinary medicines in Korea during the past decade
por: Kang, JeongWoo, et al.
Publicado: (2017)

Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021)

Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea
por: Yoo, Wan-Hee, et al.
Publicado: (2021)

Gallstones, Cholecystectomy and the Risk of Hepatobiliary and Pancreatic Cancer: A Nationwide Population-based Cohort Study in Korea
por: Huang, Dan, et al.
Publicado: (2020)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Trends in incidence and survival of esophageal cancer in Korea: Analysis of the Korea Central Cancer Registry Database
por: Shin, Aesun, et al.
Publicado: (2018)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ug9osm0f16ter8l2ob6tc7v2e6